Citi kept a Buy rating on Qiagen (QGEN) with a $55 price target while adding an “upside 90-day short-term view” on the shares. Qiagen’s “pillars of growth and strong” margin opportunity should provide a compelling backdrop for investors given the current state of the tools space, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- Cautious Optimism for Qiagen Amidst Industry Challenges: Awaiting Long-term Growth Assurance
- Qiagen’s Strong Positioning and Growth Potential Earns Buy Rating from Analyst
- Qiagen Receives Notification of BlackRock’s Voting Rights
- Qiagen’s Voting Rights Announcement Highlights BlackRock’s Influence
- Qiagen Receives Significant Voting Rights Notification from AFM